US 12161724
Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 12161724 (Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens) held by JANUX THERAPEUTICS, INC. expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- JANUX THERAPEUTICS, INC.
- Grant date
- Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K47/6843, A61K47/6849